Logo do repositório
 
Publicação

Development of secretome-based therapy by motor neuron modulation of miRNA-124 in ALS mouse models

datacite.subject.fosEngenharia e Tecnologia::Outras Engenharias e Tecnologiaspt_PT
dc.contributor.advisorBrites, Dora
dc.contributor.advisorBotelho, Ana Rita
dc.contributor.advisorBraga, Margarida
dc.contributor.authorMorais, Hermes Manuel Medina
dc.date.accessioned2021-02-02T12:43:21Z
dc.date.available2023-12-02T01:30:47Z
dc.date.issued2021-01-11
dc.date.submitted2020
dc.description.abstractAmyotrophic Lateral Sclerosis (ALS) is a fatal disease characterized by the degeneration of upper (cortical) and lower (spinal cord, SC) motor neurons (MNs) and aberrancy of glial cells. Results from our group point to a close connection between increased levels of miRNA-124 and the acquisition of pathological characteristics in MNs, astrocytes and microglia in ALS. Our main aim was to validate if the downregulation of the elevated levels of miR-124 in hSOD1G93A (mSOD1) MNs toward normal levels was preventive over neurodegeneration, astrocyte aberrancies and microglia activation in the mSOD1 mice at the early onset of the disease (10-12 weeks). Two ALS models were used: the NSC-34 MN-like cell line expressing mSOD1 (transgenic, TG) or not (wild-type, WT); and the SC organotypic cultures (OCs) from WT and TG mice. Pathological differences between TG and WT SCOCs were investigated. Relatively to the MN models, we used the modulation with pre-miR-124 (only in WT) and that of anti-miR-124 (only in the TG). The isolated secretomes were incubated in WT and TG SCOCs to assess harmful and/or neuroprotective properties. In TG SCOCs we observed: (i) increased necrotic cell death; (ii) disturbed inflammatory-associated miRNAs (increase in miR-21/miR-146a); (iii) and dysregulated neuronal and glial genes (increased CX3CR1, IL-1β, IL-10, SYP, DRP1, GLT-1 and downregulation of iNOS, HMGB1, Dlg4, CX3CL1 and GFAP). WT-MN secretome counteracted pathological markers in TG SCOCs. In contrast, TG MN secretome induced deleterious effects in WT SCOCs. Secretome from miR-124-enriched WT MNs incubated in WT SCOCs led to a profile of miRNAs and protein-coding genes similar to that caused by the TG MN secretome. On the contrary, the secretome from TG MNs depleted in miR-124 restored a deactivated profile in TG SCOCs. Our data reveals MN upregulation of miR-124 as a key player in ALS pathological processes.pt_PT
dc.description.sponsorshipCasa da Misericórdia de Lisboa (SCML), project ref. ALSResearch Grant ELA-2015-002pt_PT
dc.identifier.urihttp://hdl.handle.net/10362/111128
dc.language.isoengpt_PT
dc.relationLISBOA-01-0145-FEDER-031395pt_PT
dc.relationDevelopment of an autologous exosome-based therapy by engineering microRNAs in microglia and motor-neurons using mice and human models of amyotrophic lateral sclerosis (ALS)
dc.relationResearch Institute for Medicines
dc.relationResearch Institute for Medicines
dc.subjectAmyotrophic lateral sclerosispt_PT
dc.subjectMotor neuronpt_PT
dc.subjectGlial cellspt_PT
dc.subjectmiR-124 modulationpt_PT
dc.subjectSecretomept_PT
dc.subjectSpinal cord organotypic culturespt_PT
dc.titleDevelopment of secretome-based therapy by motor neuron modulation of miRNA-124 in ALS mouse modelspt_PT
dc.typemaster thesis
dspace.entity.typePublication
oaire.awardNumberPTDC/MED-NEU/31395/2017
oaire.awardNumberUIDB/04138/2020
oaire.awardNumberUIDP/04138/2020
oaire.awardTitleDevelopment of an autologous exosome-based therapy by engineering microRNAs in microglia and motor-neurons using mice and human models of amyotrophic lateral sclerosis (ALS)
oaire.awardTitleResearch Institute for Medicines
oaire.awardTitleResearch Institute for Medicines
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/9471 - RIDTI/PTDC%2FMED-NEU%2F31395%2F2017/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F04138%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F04138%2F2020/PT
oaire.fundingStream9471 - RIDTI
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream6817 - DCRRNI ID
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.embargofctPara publicação em revista internacional com arbitragem científica.pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typemasterThesispt_PT
relation.isProjectOfPublication76cee5b1-fa48-47f6-84dc-91efec7c58bc
relation.isProjectOfPublication0538216a-abc4-47bc-a64a-9938dd65376f
relation.isProjectOfPublicationdfe4b505-2997-4e6f-b073-0563fa49d4b6
relation.isProjectOfPublication.latestForDiscovery76cee5b1-fa48-47f6-84dc-91efec7c58bc
thesis.degree.nameMestre em Genética Molecular e Biomedicinapt_PT

Ficheiros

Principais
A mostrar 1 - 1 de 1
A carregar...
Miniatura
Nome:
Morais_2020.pdf
Tamanho:
2.83 MB
Formato:
Adobe Portable Document Format